Tom Spurling – Executive Director – Nova Eye Medical (ASX:EYE) is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
Copyright 2023 – Finance News Network
25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
03 Dec 2019 - Noxopharm Limited (ASX:NOX) Executive Chairman & CEO, Dr Graham Kelly, discusses clinical results from the company's Phase 1b clinical DARRT-1 trial for its lead product candidate, Veyonda, with low-dose radiotherapy.
22 Aug 2022 - archTIS Limited (ASX:AR9) CEO and Managing Director Daniel Lai discusses AR9's client base and growth plans, international markets, and collaborations with Microsoft and KPMG.
02 Sep 2019 - Lithium Consolidated Limited (ASX:LI3) CEO, Shanthar Pathmanathan talks about the company's capital raising and focus on hard rock lithium and sale of its US lithium brine asset to Argosy Minerals.
22 Oct 2019 - QEM Limited (ASX:QEM) Executive Director & CEO, David Fitch and GM & Chief Geologist, Scott Drelincourt discuss the company’s Julia Creek vanadium and oil shale tenements in NW QLD, drill results and strategy.
27 Apr 2020 - Aus Tin Mining (ASX:ANW) CEO, Peter Williams talks farm-in agreement for exploration licences prospective for copper and gold in the Lachlan Fold Belt and proposal to divest its Granville Tin Mine.
21 Sep 2020 - Clayton Utz Partner Brendan Bateman discusses climate change risks, the legal duties of directors and how to factor such risks into financial valuations.
29 Mar 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma, meeting its primary endpoint of progression-free survival and what it means for Immutep.
